Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1992 Sep-Oct;8(5):279-84.
doi: 10.1002/ssu.2980080506.

Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer

Affiliations
Review

Experimental models of histogenesis and tumor cell heterogeneity in bladder cancer

D Raghavan et al. Semin Surg Oncol. 1992 Sep-Oct.

Abstract

The histogenetic relationships between the subtypes of bladder cancer are not known. Each common pattern (transitional cell carcinoma, adenocarcinoma, and squamous carcinoma) can exist independently, although they may coexist in primary or metastatic bladder cancers, and tumors that are predominantly composed of transitional cell carcinoma may have regions of squamous or glandular differentiation. Morphologically identical tumors exhibit marked variation in their natural history and response to treatment. To study these aspects of the biology of human bladder cancer, a series of cell lines have been established and characterized as xenografts and in tissue culture. These studies have shown a likely common origin for transitional cell carcinoma, adenocarcinoma, and squamous carcinoma of the bladder. Morphologically similar xenografts and cell lines in vitro have shown a broad range of functional heterogeneity, including ultrastructure, tumor marker production, ploidy, cell surface characteristics, and response to chemotherapy. These are useful models of heterogeneity of response to treatment with established and new cytotoxic agents.

PubMed Disclaimer

Similar articles

Cited by

  • High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D, Taheri D, Springer S, Cowan M, Guner G, Mendoza Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Ricardo BF, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ. Nguyen D, et al. Virchows Arch. 2016 Oct;469(4):427-34. doi: 10.1007/s00428-016-2001-2. Epub 2016 Aug 12. Virchows Arch. 2016. PMID: 27520411 Free PMC article.
  • Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ. Palsgrove DN, et al. Hum Pathol. 2019 Mar;85:1-9. doi: 10.1016/j.humpath.2018.10.033. Epub 2018 Nov 14. Hum Pathol. 2019. PMID: 30447301 Free PMC article.

Publication types

LinkOut - more resources